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tal and physical component summary (MCS, PCS) and SF-6D (health utility) scores), 
productivity loss (Work Productivity and Activity Impairment questionnaire) and 
healthcare utilization in the past 6 months. Multivariable analyses were performed 
to adjust for baseline differences (e.g., age, gender, ethnicity, household income, 
insurance status, comorbidity burden, etc.). RESULTS: Among respondents with 
T2DM (n= 7,066; 39.5% female; 60.0 years), 63.0% were obese, 23.0% had SD, and 17.4% 
had obesity and SD. Multivariable analyses showed significantly worsening health 
status and greater productivity loss and healthcare utilization among respondents 
with T2DM who also had obesity or SD, or both. Respondents with T2DM/Obesity/
SD reported the poorest outcomes (vs. T2DM only): lower MCS (43.9 vs. 51.1), PCS 
(39.1 vs. 47.1), health utilities (0.62 vs. 0.73), greater absenteeism (5.5% vs. 2.0%), 
presenteeism (26.9% vs. 10.9%), overall work impairment (30.0% vs. 12.6%), activity 
impairment (43.5% vs. 21.9%), provider visits (7.7 vs. 4.6), and emergency room visits 
(0.29 vs. 0.16), all p< 0.05. CONCLUSIONS: Majority of respondents with T2DM and 
SD were obese, suggesting a strong link between obesity and SD. Coexistence of 
obesity and SD led to significantly negative impact on health status, productivity, 
and healthcare utilization in patients with T2DM. Interventions focusing on SD and 
obesity may be clinically and economically beneficial.
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OBJECTIVES: For patients with type 2 diabetes (T2DM), achieving optimal levels of 
hemoglobin A1c (HbA1c), blood pressure (BP), and LDL-cholesterol (LDL-C), or the 
“ABCs” of diabetes, has been linked to several health benefits, but goal attainment 
rates in the United States remain low. This study sought to determine how ABC goal 
attainment is associated with the presence of major depressive disorder (MDD) 
and Health-Related Quality of Life (HRQoL) among a national sample of patients 
with T2DM. METHODS: This study was a retrospective analysis of the National 
Health and Nutrition Examination Survey (NHANES) data from 2007-2012. Primary 
endpoints for ABC goal attainment were defined as HbA1c < 7%, BP < 130/80mmHg, 
and LDL-C < 100mg/dL. The study sample consisted of non-pregnant participants at 
least 20 years old with T2DM, stratified by presence of MDD. Comparisons between 
individuals who achieved and were unable to achieve simultaneous ABC goals were 
conducted using t-tests or chi-square analyses as appropriate. Multivariate logis-
tic regression was used to analyze which factors potentially influence ABC goal 
achievement. RESULTS: A total of 808 participants with T2DM met the inclusion 
criteria. The mean age for all participants was 60.5 years and 51.4% were female. 
Based on Patient Health Questionnaire (PHQ-9) scores, 11.63% of participants met 
the criteria for MDD. Overall, 23.7% of total participants were at goal for all 3 ABC 
parameters, with no significant difference in goal attainment between patients with 
or without MDD. Participants with T2DM and meeting criteria for MDD reported 
poorer general health, poorer physical health, and poorer mental health (p< 0.001 
for all) than those who did not meet criteria for MDD, according to results from the 
HRQoL survey. CONCLUSIONS: Among the study population with T2DM, presence 
of MDD showed no significant impact on ABC goal attainment. However, presence 
of MDD had a positive association with poor HRQoL.
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OBJECTIVES: Few indirect comparisons have been performed examining health-
related quality of life (HRQoL) data, owing in part to paucity of data collection. As 
health care delivery becomes increasingly patient-centered, examining HRQoL out-
comes with these methods will become important for decision making. This analysis 
utilized indirect comparison methods to assess differences in Impact of Weight on 
Quality of Life – Lite (IWQoL-Lite) total score for canagliflozin (CANA), compared 
to exenatide QW (ExQW), sitagliptin (SITA), and pioglitazone (PIO), using trial data 
evaluating these agents as add-on to metformin. METHODS: Published results 
from the DURATION-2 trial of ExQW compared to PIO and SITA, and subject-level 
data from a trial comparing CANA to SITA (DIA3006), were available for analyses. 
Disease characteristics and baseline IWQoL-Lite scores were similar, and both trials 
assessed change in IWQoL-Lite total score from baseline to Week 26. Bayesian fixed-
effect models with non-informative priors were used to estimate the difference in 
IWQoL-Lite total score for CANA (100 and 300 mg, pooled) versus ExQW, SITA, and 
PIO. Analyses were also performed to test the robustness of these results, including 
those that adjusted for potential determinants of HRQoL. RESULTS: In the unad-
justed analysis, the probability that CANA is better than ExQW, SITA, and PIO was 
60.0% (median difference [95% CrI]: –0.43 [–2.84, 3.62]), 89.9% (1.02 [–0.55, 2.58]), and 
99.5% (4.36 [1.06, 7.64]). Restricted to DURATION-2 inclusion and exclusion criteria, 
the probabilities were 61.6%, 82.1%, and 98.9%, respectively. Further adjustment 
for race and country differences yielded probabilities of 74.6% versus ExQW, 85.9% 
versus SITA, and 98.5% versus PIO. CONCLUSIONS: The adjusted analyses suggest 
that CANA is associated with at least similar IWQoL-Lite change scores compared 
to ExQW and greater improvements in IWQoL-Lite score compared to SITA and PIO. 
These analyses illustrate that indirect comparisons of HRQoL data should explore 
potential determinants of HRQoL.
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(48%), and energy/activity level (36%) for Physical; juvenalization (51%) and teasing/
bullying (33%) for Social; and self-confidence (45%) and worry (34%) for Emotional. 
Emotional and social impacts were often related to others’ perception or treat-
ment of the child as younger, and all impacts were moderated by physical growth. 
Additionally, children who began treatment later in life experienced more emotional 
and social impacts than children who started treatment at an earlier age. Children 
and caregivers reported consistent symptoms/impacts. Modifiers to the degree of 
impact of GHD were identified and include age at treatment, growth velocity, and 
having other children in family with GHD. Responses did not differ substantially 
among countries. CONCLUSIONS: Concept elicitation of the burden of disease for 
children with GHD identified key concepts that should be included in PRO/ObsRO 
measures to assess the impact of GHD and treatment.
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OBJECTIVES: To identify and compare the health outcomes profiles of adults receiv-
ing medical care at specialty clinics for symptomatic (chronic pain) and largely 
asymptomatic (diabetes) chronic conditions. METHODS: Patients receiving care at 
pain or diabetes clinic completed the PROMIS-29 instrument that measures 7 health 
domains. Item response theory-based scores are on the T-metric with a mean of 50 
and standard deviation (SD) of 10 based on the general United States population 
(norm). RESULTS: A total of 227 patients participated in the study (n= 128 chronic 
pain; n= 99 diabetes). The mean age was 46.7years (SD= 13.7), 56% were women, 
86.9% were non-Hispanic white, and 31.2% had < = 12 years of education. Pain clinic 
patients were significantly older and less educated than diabetes clinic patients, 
however there were no other demographic differences between patient groups. All 
7 domain scores were statistically significantly worse for the chronic pain clinic 
patients compared with diabetes clinic patients (P< 0.001 for all comparisons). 
The smallest and largest differences between clinics were observed for anxiety 
(mean difference= 11.4) and pain interference (mean difference= 22.0), respectively. 
Adjustment for age, sex, and education only slightly attenuated differences between 
the two patient populations. For example, the unadjusted mean difference between 
diagnostic groups for physical function was 17.7 (P< 0.001), while the mean differ-
ence was 16.02 (P< 0.001) when adjusted for demographic characteristics. The pain 
clinic sample had mean scores that were 0.9 to 1.7 SDs worse than the norm on all 
domains. CONCLUSIONS: Compared with patients with diabetes, chronic pain clinic 
patients had a substantially poorer PROMIS-29 health outcome profile. Findings indi-
cate that not only are health outcome profiles for chronic pain patients poor relative 
to the US population, but also poor relative to patients with a different chronic but 
relatively asymptomatic condition (diabetes) suggesting that aversive symptoms 
may have a more significant impact than chronic disease per se.
PDB82
utIlIzInG tHe sf-36v2 mental comPonent summary score to DescrIBe 
mental well-BeInG exPerIenceD By PatIents wItH tyPe 2 DIaBetes
Bolge S.C.1, Flores N.M.2, Phan J.1
1Janssen Scientific Affairs, LLC, Raritan, NJ, USA, 2Kantar Health, Foster City, CA, USA
OBJECTIVES: To measure the mental well-being experienced by patients with 
type 2 diabetes (T2D) by utilizing the SF-36v2 mental component summary 
(MCS). METHODS: Data were from the 2013 U.S. National Health and Wellness 
Survey. Respondents (aged ≥ 18 years) provided details about their health status 
and health care through self-administered, Internet-based questionnaires. The 
analytic sample included those self-reporting a T2D diagnosis. Mental well-being 
was defined by utilizing the SF-36v2 MCS. Based on the normed mean of 50 and 
standard deviation (SD) of 10 for the general population and the distribution of 
MCS scores within the analytic sample, categories were defined as good mental 
well-being (above the population mean; MCS ≥ 50), poor mental well-being (≤ 1 SD 
below the population mean; MCS ≥ 40 and < 50), and very poor mental well-being (> 1 
SD below the population mean; MCS< 40). RESULTS: The analytic sample consisted 
of 7852 respondents diagnosed with T2D. Of these, 22% (n= 1701) experienced very 
poor mental well-being, 23% (n= 1781) poor mental well-being, and 56% (n= 4370) 
good mental well-being. Very poor/poor mental well-being was associated with 
respondents who were younger, female, non-white, less educated, current smokers, 
and had lower household income (p< 0.001 for all). Respondents with very poor/poor 
mental well-being vs. good mental well-being had greater Charlson Comorbidity 
Index scores (mean of 1.99/1.77 vs. 1.59), and were more likely to be diagnosed with 
depression (57%/26% vs. 5%) or an anxiety disorder (44%/20% vs. 5%) (p< 0.001 for 
all). Poorer mental well-being also was associated with having T2D for a shorter 
period of time, use of insulin, experience with hypoglycemia, and greater likelihood 
of T2D related complications (p< 0.001 for all). CONCLUSIONS: Poorer mental well-
being, as measured by the SF-36v2 MCS, is associated with greater overall physical 
and psychiatric morbidity, as well as morbidity specifically associated with T2D.
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OBJECTIVES: Obesity is a strong risk factor for sleep disorders (SD) and type 2 dia-
betes mellitus (T2DM). SD and T2DM are often associated. This study examined the 
incremental burden of obesity and SD in patients with T2DM. METHODS: Data were 
analyzed from the 2012 US National Health and Wellness Survey, a nationally repre-
sentative, online survey of 71,157 adults (≥ 18 years). Respondents with T2DM were 
categorized into 4 groups: T2DM only; T2DM with obesity; T2DM with SD; T2DM with 
obesity and SD. Respondents provided information on health status (SF-36v2: men-
